Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:37PM ET
43.77
Dollar change
+0.46
Percentage change
1.06
%
IndexRUT P/E- EPS (ttm)-1.96 Insider Own11.68% Shs Outstand74.56M Perf Week-4.08%
Market Cap3.26B Forward P/E- EPS next Y-1.81 Insider Trans-3.04% Shs Float65.85M Perf Month-1.79%
Income-112.96M PEG- EPS next Q-0.51 Inst Own80.95% Short Float13.39% Perf Quarter23.85%
Sales23.39M P/S139.53 EPS this Y-10.84% Inst Trans15.16% Short Ratio9.47 Perf Half Y65.98%
Book/sh9.55 P/B4.58 EPS next Y16.66% ROA-21.78% Short Interest8.82M Perf Year221.37%
Cash/sh7.04 P/C6.21 EPS next 5Y- ROE-23.28% 52W Range13.29 - 47.74 Perf YTD23.02%
Dividend Est.- P/FCF- EPS past 5Y-2.95% ROI-18.15% 52W High-8.31% Beta0.80
Dividend TTM- Quick Ratio19.65 Sales past 5Y14.24% Gross Margin83.03% 52W Low229.35% ATR (14)1.77
Dividend Ex-Date- Current Ratio19.65 EPS Y/Y TTM-40.58% Oper. Margin-574.85% RSI (14)48.63 Volatility3.29% 4.12%
Employees124 Debt/Eq0.00 Sales Y/Y TTM-54.08% Profit Margin-483.05% Recom1.09 Target Price53.27
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-3.50% Payout- Rel Volume0.41 Prev Close43.31
Sales Surprise-55.64% EPS Surprise-11.18% Sales Q/Q-2.46% EarningsFeb 20 BMO Avg Volume931.07K Price43.77
SMA20-1.88% SMA50-1.15% SMA20036.82% Trades Volume191,184 Change1.06%
Date Action Analyst Rating Change Price Target Change
Mar-08-24Initiated BTIG Research Buy $55
Aug-08-23Initiated SVB Securities Outperform $33
May-24-23Initiated Goldman Buy $32
Apr-24-23Upgrade Stifel Hold → Buy $18 → $24
Mar-23-23Initiated Berenberg Buy $26
Feb-28-23Initiated RBC Capital Mkts Outperform $25
Dec-28-22Initiated CapitalOne Overweight $29
Oct-27-22Initiated Citigroup Buy $26
Aug-15-22Downgrade Stifel Buy → Hold $16 → $13
Jul-18-22Resumed Oppenheimer Outperform $25
Mar-27-24 09:25AM
Mar-12-24 06:00AM
Mar-04-24 06:00AM
Feb-20-24 06:36AM
06:00AM
05:37AM Loading…
Feb-13-24 05:37AM
Feb-01-24 06:00AM
Jan-26-24 06:00AM
Jan-18-24 01:03AM
Jan-15-24 07:03AM
Jan-07-24 09:00AM
Dec-29-23 06:00AM
Dec-08-23 06:00AM
Dec-05-23 06:00AM
Dec-04-23 06:00AM
09:00AM Loading…
Dec-03-23 09:00AM
Nov-14-23 09:55AM
Nov-07-23 07:15AM
06:44AM
06:00AM
Nov-01-23 06:00AM
Oct-27-23 04:02PM
06:00AM
Oct-25-23 11:55AM
Oct-24-23 10:15PM
04:07PM
Oct-23-23 06:00AM
Oct-18-23 08:33AM
Oct-17-23 06:00AM
Oct-16-23 06:00AM
06:00AM Loading…
Oct-09-23 06:00AM
Oct-06-23 06:00AM
Sep-27-23 06:00AM
Sep-26-23 06:00AM
Sep-15-23 01:03PM
Sep-11-23 06:00AM
Sep-05-23 06:00AM
Aug-21-23 06:00AM
Aug-16-23 06:00AM
Aug-10-23 07:15AM
06:00AM
Aug-08-23 10:02AM
Aug-02-23 06:00AM
Aug-01-23 06:00AM
Jul-28-23 06:00AM
Jun-30-23 06:00AM
Jun-22-23 06:00AM
Jun-12-23 06:00AM
Jun-11-23 09:56AM
May-30-23 06:00AM
May-26-23 06:00AM
May-22-23 06:00AM
May-16-23 06:00AM
May-09-23 07:25AM
06:00AM
May-04-23 10:00AM
May-02-23 10:02AM
May-01-23 06:00AM
Apr-29-23 09:00AM
Apr-28-23 06:00AM
Apr-27-23 04:01PM
Apr-25-23 05:44AM
12:15AM
Apr-24-23 04:12PM
12:13PM
Apr-23-23 09:00AM
Apr-19-23 06:00AM
Apr-16-23 09:50AM
Apr-03-23 06:00AM
Mar-31-23 06:00AM
Mar-27-23 09:55AM
Mar-14-23 04:31PM
Mar-07-23 07:15AM
06:00AM
Mar-01-23 06:00AM
Feb-16-23 06:00AM
Feb-01-23 06:00AM
Jan-23-23 06:00AM
Jan-09-23 06:00AM
Jan-03-23 06:00AM
Jan-01-23 08:50AM
Dec-19-22 06:00AM
Dec-12-22 06:00AM
Dec-05-22 09:55AM
06:00AM
Nov-29-22 06:00AM
Nov-28-22 06:00AM
Nov-17-22 01:58PM
Nov-16-22 09:55AM
Nov-10-22 05:02AM
Nov-08-22 07:35AM
06:00AM
Nov-01-22 06:00AM
Oct-18-22 09:09AM
06:00AM
Sep-21-22 06:52AM
Sep-19-22 04:01PM
Sep-14-22 10:41PM
04:39PM
Sep-13-22 11:18AM
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hata Yujiro SPresident and CEOFeb 09 '24Option Exercise4.3123,557101,531701,444Feb 12 04:27 PM
Hata Yujiro SPresident and CEOFeb 09 '24Sale45.5423,5571,072,715677,887Feb 12 04:27 PM
Ruiz Briseno AndresSee RemarksFeb 09 '24Sale46.022,00092,04524,531Feb 13 04:59 PM
Hata Yujiro SPresident and CEOFeb 08 '24Option Exercise4.3175,815326,763753,702Feb 12 04:27 PM
Hata Yujiro SPresident and CEOFeb 08 '24Sale45.1575,8153,422,835677,887Feb 12 04:27 PM
Hata Yujiro SPresident and CEOFeb 01 '24Option Exercise4.316282,707678,515Feb 05 06:05 PM
Hata Yujiro SPresident and CEOFeb 01 '24Sale45.0062828,260677,887Feb 05 06:05 PM
Ruiz Briseno AndresSee RemarksJan 22 '24Sale42.032,00084,05026,531Jan 24 07:12 PM
Hata Yujiro SPresident and CEOJan 16 '24Option Exercise4.3162,739270,405740,626Jan 17 05:40 PM
Hata Yujiro SPresident and CEOJan 16 '24Sale40.1762,7392,519,968677,887Jan 17 05:40 PM
Hata Yujiro SPresident and CEOJan 12 '24Option Exercise4.3112,26152,845690,148Jan 17 05:40 PM
Hata Yujiro SPresident and CEOJan 12 '24Sale40.0412,261490,913677,887Jan 17 05:40 PM
Ruiz Briseno AndresSee RemarksJan 12 '24Sale38.012,00076,02628,531Jan 17 05:41 PM
Throne JasonChief Legal OfficerDec 18 '23Option Exercise7.0110,00070,10010,000Dec 19 05:37 PM
Hata Yujiro SPresident and CEODec 15 '23Option Exercise4.3175,000323,250752,887Dec 19 05:34 PM
Throne JasonChief Legal OfficerDec 15 '23Option Exercise13.3410,000133,40010,000Dec 19 05:37 PM
Hata Yujiro SPresident and CEODec 15 '23Sale35.0375,0002,627,618677,887Dec 19 05:34 PM
Throne JasonChief Legal OfficerDec 15 '23Sale35.0410,000350,3710Dec 19 05:37 PM
Ruiz Briseno AndresSee RemarksDec 14 '23Sale34.002,00068,00230,531Dec 18 05:45 PM
Throne JasonChief Legal OfficerNov 03 '23Option Exercise12.865,16366,3965,163Nov 07 05:47 PM
Throne JasonChief Legal OfficerNov 03 '23Sale30.095,163155,3600Nov 07 05:47 PM
Throne JasonChief Legal OfficerSep 12 '23Option Exercise12.861,00012,8601,000Sep 14 05:23 PM
Throne JasonChief Legal OfficerSep 12 '23Sale30.001,00030,0050Sep 14 05:23 PM
Throne JasonChief Legal OfficerSep 05 '23Option Exercise12.861,73722,3381,737Sep 06 06:37 PM
Throne JasonChief Legal OfficerSep 05 '23Sale30.031,73752,1600Sep 06 06:37 PM
Throne JasonChief Legal OfficerSep 01 '23Option Exercise12.862,10027,0062,100Sep 06 06:37 PM
Throne JasonChief Legal OfficerSep 01 '23Sale30.032,10063,0630Sep 06 06:37 PM
Ruiz Briseno AndresSee RemarksSep 01 '23Sale30.012,00060,01632,531Sep 06 06:36 PM
Stone Paul A.Chief Financial OfficerAug 29 '23Sale28.875,000144,3529,303Aug 31 05:49 PM
Stone Paul A.Chief Financial OfficerAug 21 '23Sale26.4097825,81914,303Aug 23 06:31 PM
Stone Paul A.Chief Financial OfficerAug 18 '23Sale26.383,822100,82015,281Aug 18 06:33 PM
Stone Paul A.Chief Financial OfficerAug 16 '23Sale26.432005,28519,103Aug 18 06:33 PM
Throne JasonChief Legal OfficerAug 09 '23Option Exercise13.345,00066,7005,000Aug 11 07:22 PM
Throne JasonChief Legal OfficerAug 09 '23Sale25.095,000125,4300Aug 11 07:22 PM
Stone Paul A.Chief Financial OfficerAug 09 '23Sale25.052,50062,61319,303Aug 11 07:21 PM
Throne JasonChief Legal OfficerJul 10 '23Option Exercise10.099,48595,7409,485Jul 12 05:25 PM
Throne JasonChief Legal OfficerJul 10 '23Sale23.009,485218,1780Jul 12 05:25 PM
Throne JasonChief Legal OfficerJun 01 '23Option Exercise7.013,55324,9073,553Jun 02 05:29 PM
Throne JasonChief Legal OfficerJun 01 '23Sale23.023,55381,7920Jun 02 05:29 PM
Throne JasonChief Legal OfficerMay 31 '23Option Exercise7.014323,028432Jun 02 05:29 PM
Throne JasonChief Legal OfficerMay 31 '23Sale23.004329,9380Jun 02 05:29 PM
Throne JasonChief Legal OfficerMay 22 '23Option Exercise7.015003,505500May 24 05:51 PM
Throne JasonChief Legal OfficerMay 22 '23Sale23.0050011,5000May 24 05:51 PM
Stone Paul A.Chief Financial OfficerApr 13 '23Option Exercise4.628,00036,96021,803Apr 14 01:20 PM
Hata Yujiro SPresident and CEOApr 12 '23Option Exercise4.3111,60150,000677,887Apr 13 04:11 PM